An evaluation of factors impacting the survival of Manitoba women with ovarian cancer treated with neoadjuvant chemotherapy

Simple item page
dc.contributor.authorMayba, Julia
dc.date.accessioned2018-07-10T19:40:55Z
dc.date.available2018-07-10T19:40:55Z
dc.date.issued2016
dc.date.submitted2018-07-10T19:40:55Zen
dc.description.abstractPrior analyses by the Manitoba Ovarian Cancer Outcomes study group identified that late-stage ovarian cancer patients receiving neoadjuvant chemotherapy had poorer survival than patients receiving adjuvant chemotherapy. This is consistent with other observational studies identifying neoadjuvant survival being worse compared to adjuvant survival. Additional investigations into potential causes behind poorer neoadjuvant survival in Manitoba between the years 2004-2010 were conducted. In this thesis project, possible predictors of neoadjuvant treatment were examined. Furthermore, a series of clinical questions were generated to investigate the effects of treatment-related factors on neoadjuvant patient survival, such as residual tumour post-surgery, chemotherapy-induced toxicities, chemotherapy dose reduction, delay in chemotherapy treatment, and the number of cycles of chemotherapy. It was determined that predictors of neoadjuvant treatment included older age, unclassified epithelial tumour histotype, and a short time period (0-50 days) from suspicion to diagnosis of malignancy. Variables that did not substantially affect neoadjuvant patient survival included chemotherapy dose reduction, chemotherapy dose interruption, chemotherapy toxicities, and absence of residual tumour post surgery. However, neoadjuvant patients were more likely to require more than one line of chemotherapy, which might contribute to their increased risk of death. It appears that neoadjuvant patients likely present with greater disease severity compared to adjuvant patients. This may lead to clinical selection bias, whereby sicker patients are appropriately treated with neoadjuvant chemotherapy. This study demonstrated that poor survival in the neoadjuvant patient population is due to greater disease severity upon presentation, unfavourable tumour histotype, and later disease stage resulting in treatment with neoadjuvant chemotherapy.en_US
dc.description.sponsorshipCancerCare Manitobaen_US
dc.identifier.urihttp://hdl.handle.net/1993/33110
dc.rightsopen accessen_US
dc.subjectovarian canceren_US
dc.subjectManitobaen_US
dc.subjectneoadjuvant chemotherapyen_US
dc.subjectManitoba Ovarian Cancer Outcomesen_US
dc.titleAn evaluation of factors impacting the survival of Manitoba women with ovarian cancer treated with neoadjuvant chemotherapyen_US
dc.typebachelor thesisen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Mayba, Julia Final Report.pdf
Size:
1.01 MB
Format:
Adobe Portable Document Format
Description:
BSc(Med) Final Research Report
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed to upon submission
Description:
Download
Collections
College of Medicine - B.Sc. (Med) Projects